Guidance Documents for Off‐Label Drug Use Management for Chinese Health Care Institutions: A Scoping Review
- 23 December 2024
- journal article
- review article
- Published by Wiley in Journal of Evidence-Based Medicine
- Vol. 17 (4) , 808-821
Abstract
Background: Off‐label drug use (OLDU) is a common practice in health care institutions, and numerous guidance documents have been developed to guide the management of OLDU in China. This scoping review aims to compare these documents and identify existing issues.Methods: PubMed, EMbase, three Chinese databases, the National Public Service Platform for Standards Information and the official websites of pharmaceutical‐related associations were searched to identify guidance documents relevant to the management of OLDU for Chinese health care institutions. We extracted and compared the recommended practices for various aspects of OLDU management, including management systems, organizational structure, prerequisites for OLDU, approval processes, evidence‐based evaluation, informed consent, and other related aspects.Results: A total of 16 guidance documents were included, comprising 12 expert consensuses, 2 practice guidelines, and 2 group standards. Only six documents provide specific requirements for the establishment of management systems. Management of OLDU requires involvement from multiple departments or committees, yet only a few documents explicitly delineate the supervisory authority, and the responsibilities of the parties involved. These documents also show significant disparities in their approval process, evidence‐based evaluation, and informed consent recommendations. Furthermore, only a minority of the documents provide specific requirements for training and assessments focused on OLDU and improving adverse reaction monitoring.Conclusion: These guidance documents differ significantly in their specific recommendations for the management of OLDU and lack sufficient emphasis on certain critical aspects. It may be beneficial for health administrative authorities to promote the development of unified national guidelines.Keywords
Funding Information
- Medical and Health Research Project of Zhejiang Province (2025KY1093)
This publication has 30 references indexed in Scilit:
- Evaluation of off-label medication use and drug safety in a pediatric intensive care unitSaudi Pharmaceutical Journal, 2023
- Off-label use of immune checkpoint inhibitors for the treatment of solid tumors: analysis of a nationwide patient sampleJournal of Cancer Research and Clinical Oncology, 2023
- Management guideline for the off-label use of medicine in China (2021)Expert Review of Clinical Pharmacology, 2022
- Evaluation of Clinical Compendia Used for Medicare Part D Coverage Determinations for Off-label Prescribing in DermatologyJAMA Dermatology, 2019
- Non-regulatory related factors leading to off-label prescribing in children: A concept mapResearch in Social and Administrative Pharmacy, 2017
- Association of Off-label Drug Use and Adverse Drug Events in an Adult PopulationJAMA Internal Medicine, 2016
- A Multicenter Evaluation of Off-Label Medication Use and Associated Adverse Drug Reactions in Adult Medical ICUsCritical Care Medicine, 2015
- Adverse drug reactions and off-label and unlicensed medicines in children: a prospective cohort study of unplanned admissions to a paediatric hospitalBritish Journal of Clinical Pharmacology, 2014
- Ten Common Questions (and Their Answers) About Off-label Drug UseMayo Clinic Proceedings, 2012
- Off-label Prescribing Among Office-Based PhysiciansArchives of internal medicine (1960), 2006